Transactions in Own Shares & Buyback Update

Haleon PLC

19 August 2026

Haleon plc: Aggregated information - transactions in own shares and update on the Buyback Programme

19 August 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,569,800 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE	Aquis
Date of purchase:	17 August 2026
Number of Shares purchased:	451,463	271,801	276,736	-
Highest price paid per Share (p):	352.5000	352.5000	352.5000	-
Lowest price paid per Share (p):	350.9000	350.8000	350.9000	-
Volume weighted average price paid per Share (p):	352.0396	351.8880	351.9907	-
Date of purchase:	18 August 2026
Number of Shares purchased:	233,766	130,438	205,596	-
Highest price paid per Share (p):	356.5000	356.4000	356.5000	-
Lowest price paid per Share (p):	348.9000	348.9000	348.9000	-
Volume weighted average price paid per Share (p):	352.4474	352.4242	352.7530	-

Following the settlement of the above, the Company's registered share capital is 8,808,341,409 ordinary shares of £0.01 each, of which 11,807,443 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,796,533,966 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2078R_1-2026-8-18.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Completion of the Buyback Programme

Following the above transactions, Haleon has completedthe £500m share buyback programme announced on 12 March 2026.

Since the start of the year, the Company has repurchased 144,012,239 Shares, all of which were cancelled.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visitwww.haleon.com. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.